Psychedelics remain classified as Schedule I substances under federal law, subject to severe legal penalties despite mounting scientific evidence of their therapeutic potential and low risk of direct harm. In this position paper, D4DPR recommends that statewide decriminalization is a necessary step toward an evidence-based drug policy that shifts focus from punishment to public health, harm reduction, and social equity.
Kristel Carrington, MD was the principal developer and author of this position paper.
.svg)